{
  "id": 14094399,
  "title": "T cell engagers convert acute tumor killing into endogenous vaccination",
  "url": "https://urgent.news/2026/10/12/t-cell-engagers-convert-acute-tumor-killing-into-endogenous",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-12T00:00:00.000Z",
  "source": {
    "name": "bioRxiv",
    "slug": "biorxiv",
    "url": "https://www.biorxiv.org/content/10.64898/2026.10.06.756695v1?rss=1"
  },
  "original_language": "en",
  "account": "T cell engagers (TCEs) have been found to transform short-term tumor killing into a long-lasting endogenous vaccination, according to a study using mouse models. TCEs work by linking CD3ε to a tumor antigen, independently of the T cell receptor specificity, which prompts the immune system to mount a potent response. While some patients experience persistent remission following TCE treatment, the connection between the immediate cytotoxicity and the development of lasting adaptive immunity had remained unclear. The researchers employed immunocompetent mouse models for clinically-generated human TCEs to investigate this relationship further. Utilizing intravital two-photon imaging, they observed a cytotoxic wave initiated by TCE-mediated killing that peaked within 24 hours, followed by a persistent accumulation of T cells. Single-cell transcriptomics and adoptive transfers revealed that memory CD8 T cells, the primary effector reservoirs, transition through a progenitor-like state before becoming cytotoxic effectors with recall capability. More importantly, the tumor lysis facilitated by the TCEs acted as a cross-primer for tumor-specific CD8 T cells by activating type 1 conventional dendritic cells, a cDC1-dependent process crucial for durable tumor control and the formulation of protective memory upon rechallenge.",
  "summary": "T cell engagers (TCEs) redirect T cells to kill tumors by cross-linking CD3{varepsilon} to a tumor antigen, independently of T cell receptor specificity. Some patients achieve remissions that persist long after drug clearance, but whether TCEs can couple acute cytotoxicity to the generation of lasting adaptive immunity remains unknown. Here, using an immunocompetent mouse model for clinical-grade…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}